KR102011770B1 - 치환된 피리도피리미딘 화합물 및 flt3 억제제로서의 이의 용도 - Google Patents

치환된 피리도피리미딘 화합물 및 flt3 억제제로서의 이의 용도 Download PDF

Info

Publication number
KR102011770B1
KR102011770B1 KR1020147029509A KR20147029509A KR102011770B1 KR 102011770 B1 KR102011770 B1 KR 102011770B1 KR 1020147029509 A KR1020147029509 A KR 1020147029509A KR 20147029509 A KR20147029509 A KR 20147029509A KR 102011770 B1 KR102011770 B1 KR 102011770B1
Authority
KR
South Korea
Prior art keywords
compound
amino
disease
bromo
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020147029509A
Other languages
English (en)
Korean (ko)
Other versions
KR20140144709A (ko
Inventor
김홍우
이희규
송호준
이재규
고종성
김중호
김세원
이인영
Original Assignee
주식회사 오스코텍
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 오스코텍 filed Critical 주식회사 오스코텍
Publication of KR20140144709A publication Critical patent/KR20140144709A/ko
Application granted granted Critical
Publication of KR102011770B1 publication Critical patent/KR102011770B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/305—Mercury compounds
    • A61K31/31—Mercury compounds containing nitrogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020147029509A 2012-03-22 2013-03-15 치환된 피리도피리미딘 화합물 및 flt3 억제제로서의 이의 용도 Active KR102011770B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261614274P 2012-03-22 2012-03-22
US61/614,274 2012-03-22
PCT/US2013/032575 WO2013142382A1 (en) 2012-03-22 2013-03-15 Substituted pyridopyrimidine compounds and their use as flt3 inhibitors

Publications (2)

Publication Number Publication Date
KR20140144709A KR20140144709A (ko) 2014-12-19
KR102011770B1 true KR102011770B1 (ko) 2019-08-19

Family

ID=49223277

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147029509A Active KR102011770B1 (ko) 2012-03-22 2013-03-15 치환된 피리도피리미딘 화합물 및 flt3 억제제로서의 이의 용도

Country Status (21)

Country Link
US (1) US8877763B2 (https=)
EP (1) EP2828259B1 (https=)
JP (1) JP6101341B2 (https=)
KR (1) KR102011770B1 (https=)
CN (1) CN104428298B (https=)
AU (1) AU2013235344B2 (https=)
BR (1) BR112014023460B1 (https=)
CA (1) CA2868156C (https=)
CL (1) CL2014002505A1 (https=)
EA (1) EA031267B1 (https=)
ES (1) ES2694223T3 (https=)
IL (1) IL234802B (https=)
IN (1) IN2014MN02082A (https=)
MX (1) MX360912B (https=)
MY (1) MY184858A (https=)
NZ (1) NZ700283A (https=)
PL (1) PL2828259T3 (https=)
SG (1) SG11201405942RA (https=)
TR (1) TR201816480T4 (https=)
WO (1) WO2013142382A1 (https=)
ZA (1) ZA201407588B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102440707B1 (ko) 2022-07-10 2022-09-05 이우미 공장 추천 시스템

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3060562T3 (pl) * 2013-10-21 2022-01-10 Genosco Podstawione związki pirymidynowe i ich zastosowanie jako inhibitory syk
US10065934B2 (en) * 2014-07-17 2018-09-04 Sunshine Lake Pharma Co., Ltd. Substituted urea derivatives and pharmaceutical uses thereof
KR20160035411A (ko) * 2014-09-23 2016-03-31 주식회사 오스코텍 LRRK2 (Leucine Rich Repeat Kinase 2) 키나제 억제제로서의 피리도피리미딘 유도체 화합물
US11608340B2 (en) 2014-11-17 2023-03-21 Rhode Island Hospital Nanomaterial compositions, synthesis, and assembly
AU2019292207B2 (en) * 2018-06-27 2022-06-30 Oscotec Inc. Pyridopyrimidinone derivatives for use as Axl inhibitors
KR20200022712A (ko) 2018-08-23 2020-03-04 주식회사 오스코텍 8-브로모-2-(1-메틸피페리딘-4-일아미노)-4-(4-페녹시페닐아미노)피리도[4,3-d]피리미딘-5(6H)-온 염산염의 결정다형체 및 그 제조방법
KR102230721B1 (ko) 2019-02-01 2021-03-22 주식회사 오스코텍 피리도피리미딘계 염산염을 포함하는 경구용 고형제제 및 이의 제조방법
EA202192575A1 (ru) 2019-03-21 2022-01-14 Онксео Соединения dbait в сочетании с ингибиторами киназ для лечения рака
CN110327347B (zh) * 2019-08-16 2021-06-01 陕西科技大学 G-749在制备抗真菌药物中的应用
TWI759829B (zh) * 2019-08-23 2022-04-01 財團法人生物技術開發中心 作為第iii型受體酪胺酸激酶抑制劑之雜環吡唑衍生物
CN114761006A (zh) 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) 对激酶抑制剂产生耐药性的癌症的治疗方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2023027966A1 (en) 2021-08-24 2023-03-02 Biomea Fusion, Inc. Pyrazine compounds as irreversible inhibitors of flt3
MX2024008057A (es) 2021-12-30 2024-08-28 Biomea Fusion Inc Compuestos de pirazina como inhibidores de flt3.
WO2023225005A1 (en) 2022-05-17 2023-11-23 Biomea Fusion, Inc. Flt3 combination therapy for cancer and compositions therefor

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010019637A1 (en) 2008-08-12 2010-02-18 Smithkline Beecham Corporation Chemical compounds
WO2011053861A1 (en) 2009-10-29 2011-05-05 Genosco Kinase inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003523358A (ja) * 2000-01-27 2003-08-05 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 神経変性疾患の治療のためのピリドピリミジノン誘導体
CA2420286A1 (en) * 2000-08-31 2002-03-07 F. Hoffmann-La Roche Ag 7-oxo pyridopyrimidines as inhibitors of a cellular proliferation
CA2420122A1 (en) * 2000-08-31 2002-03-07 F. Hoffmann-La Roche Ag 7-oxo pyridopyrimidines
EP2025678A1 (en) * 2007-08-17 2009-02-18 Oncalis AG Pyrazolo[3,4-d]pyrimidine compounds and their use as modulators of protein kinase
TW200938542A (en) * 2008-02-01 2009-09-16 Irm Llc Compounds and compositions as kinase inhibitors
US8338481B2 (en) * 2009-01-28 2012-12-25 Ramot At Tel-Aviv University Ltd. Alkoxyalkyl S-prenylthiosalicylates for treatment of cancer
MX2012001974A (es) * 2009-08-19 2012-04-11 Ambit Biosciences Corp Compuestos de biarilo y metodos de uso de los mismos.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010019637A1 (en) 2008-08-12 2010-02-18 Smithkline Beecham Corporation Chemical compounds
WO2011053861A1 (en) 2009-10-29 2011-05-05 Genosco Kinase inhibitors

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102440707B1 (ko) 2022-07-10 2022-09-05 이우미 공장 추천 시스템

Also Published As

Publication number Publication date
MX2014011354A (es) 2014-12-05
ES2694223T3 (es) 2018-12-19
WO2013142382A1 (en) 2013-09-26
AU2013235344B2 (en) 2017-03-16
PL2828259T3 (pl) 2019-02-28
AU2013235344A1 (en) 2014-10-09
MX360912B (es) 2018-11-22
EP2828259A1 (en) 2015-01-28
CA2868156A1 (en) 2013-09-26
CA2868156C (en) 2020-07-28
EP2828259B1 (en) 2018-08-08
JP2015510942A (ja) 2015-04-13
CL2014002505A1 (es) 2015-10-02
IN2014MN02082A (https=) 2015-08-21
US8877763B2 (en) 2014-11-04
SG11201405942RA (en) 2014-10-30
EA201491747A1 (ru) 2015-10-30
CN104428298A (zh) 2015-03-18
EP2828259A4 (en) 2015-08-19
EA031267B1 (ru) 2018-12-28
MY184858A (en) 2021-04-27
TR201816480T4 (tr) 2018-11-21
CN104428298B (zh) 2017-03-01
IL234802B (en) 2018-10-31
BR112014023460B1 (pt) 2020-09-01
HK1208453A1 (en) 2016-03-04
NZ700283A (en) 2016-08-26
KR20140144709A (ko) 2014-12-19
US20130274274A1 (en) 2013-10-17
JP6101341B2 (ja) 2017-03-22
ZA201407588B (en) 2015-11-25

Similar Documents

Publication Publication Date Title
KR102011770B1 (ko) 치환된 피리도피리미딘 화합물 및 flt3 억제제로서의 이의 용도
EP2493313B1 (en) Kinase inhibitors
KR101686685B1 (ko) 피라졸로피리미딘 ｊａｋ 억제제 화합물 및 방법
KR102851010B1 (ko) 포스파티딜이노시톨 3-키나제 저해제
US9550796B2 (en) Pyrrolopyrrolone derivatives and their use as BET inhibitors
TWI707855B (zh) 咪唑并嗒類化合物及其用途
WO2014191894A1 (en) Imidazopyrrolidinone derivatives and their use in the treatment of disease
EP2945623A1 (en) Hedgehog pathway signaling inhibitors and therapeutic applications thereof
JPWO2015022926A1 (ja) 新規な縮合ピリミジン化合物又はその塩
EP4370124A1 (en) PI3Ka INHIBITORS AND METHODS OF USE THEREOF
TW202204351A (zh) 具有大環結構的化合物及其用途
CN119343346A (zh) 苯磺酰胺衍生物、其制备方法及含有其作为活性成分的预防或治疗癌症的药物组合物
KR20210014212A (ko) Axl 억제제로 사용하기 위한 피리도피리미디논 유도체
HK1208453B (en) Substituted pyridopyrimidine compounds and their use as flt3 inhibitors
TW202604514A (zh) 作為pi3k 抑制劑之含稠合三環之化合物
AU2010313240B2 (en) Kinase inhibitors
HK1175367A (en) Kinase inhibitors

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R19-X000 Request for party data change rejected

St.27 status event code: A-3-3-R10-R19-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

X091 Application refused [patent]
R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

P14-X000 Amendment of ip right document requested

St.27 status event code: A-5-5-P10-P14-nap-X000

FPAY Annual fee payment

Payment date: 20220810

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

P14-X000 Amendment of ip right document requested

St.27 status event code: A-5-5-P10-P14-nap-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 7